CCT303-406

N/A

Report date: 2025/02/06 16:11:34

Base Information

Drug NameCCT303-406

Drug Alias NameCCT3-HER2-0406CCT303-406

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsStomach Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBioAtla Inc

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Sinobioway Sunterra Biotech

Inactive CompaniesN/A

Active IndicationsSolid tumoursOvarian NeoplasmsStomach Neoplasms +[5]

Inactive IndicationsN/A

Other Information

ATC CodeN/A